John Climaco
CEO, President & Director
Welcome, everyone. The Annual Meeting of the Stockholders of CNS Pharmaceuticals, Inc. is hereby convened and called to order. I’m John Climaco, CEO and President of CNS Pharmaceuticals, Inc., and I welcome all of you to the company’s Annual Meeting of Stockholders. Christopher Downs, the Chief Financial Officer of the company by active Secretary of the meeting and Inspector of the election.
This meeting has been called pursuant to do notice. Proxies were solicited on behalf of the Board of Directors of the company for this meeting. A copy of the proxy statement dated October 24, 2025, and formal proxy are available for inspection and will be attached to the minutes of this meeting. As of the record date for the meeting, October 10, 2025, we had 574,580 shares of the company’s common stock outstanding and entitled to vote of the one book per share. For there to be a quorum for the consideration of matters to be voted upon at this meeting, shares representing 1/3 of the bots that may be cast by all outstanding shares of common stock as a director, that must be present in person or by proxy to hold the meeting.
I would appreciate all stockholders who are present in person and the holders of proxies for stockholders who have not already done so at this time to sign the register and present their proxies to the inspector of election so that he may make a tabulation of the number of stockholders present Will the inspector of election kindly submit his report of the number of votes represented by the shares of
Read the full article here
